First quarter in brief: · Sales growth was 12 percent in local currency. Sales amounted to SEK 119 (105) million, corresponding to an increase of 14 percent in SEK. · Operating income (EBIT) amounted to SEK 30 (17) million, corresponding to an operating margin of 25 (16) percent. Operating income included a recovered additional purchase price of SEK 2 million regarding the acquisition of Cryo Management Ltd. Adjusted for this, the operating margin amounted to 23 (16) percent. · Net income amounted to SEK 22 (12) million, which gave earnings per share of SEK 1.12 (0.60). Gothenburg, April 23, 2014 VITROLIFE AB (publ) Thomas Axelsson, CEO Queries should be addressed to: Thomas Axelsson, CEO, tel 46 31 721 80 01 Mikael Engblom, CFO, tel 46 31 721 80 14 Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on April 23, 2014 at 08:30 a.m. This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails. _________________________________________________________________________________________________________________ Vitrolife (http://www.vitrolife.com/en/Corporate/) is an international medical device Group. Vitrolife Fertility (http://www.vitrolife.com/en/Fertility/) product area develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes Vitrolife (http://www.vitrolife.com/en/Corporate/) has approximately 240 employees and the company's products are sold in almost 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The Vitrolife share (http://www.vitrolife.com/en/Corporate/Financial/The-share1/) is listed on NASDAQ OMX Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE13469), Small Cap. _________________________________________________________________________________________________________________ Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/ ----------------------------------------------------------- http://news.cision.com/vitrolife-ab--publ-/r/interim-report-january-march-2014--strengthened-operating-margin,c9572278 http://mb.cision.com/Main/1031/9572278/235631.pdf